This CBD-Intel hub covers regulation at the overarching US government level.
The US House of Representatives is expected to hold a historic vote this month on a comprehensive cannabis reform bill that supporters embrace for not only decriminalising marijuana but correcting injustices
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
First it’s important to note that the DEA proposals are only in a draft form and are open to comment until 20th October. They have already received a large number of comments, the majority of which appear to be criticising aspects of the proposed regulatory regime that have raised hackles among the industry.
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
Proposed regulations from the US Drug Enforcement Administration (DEA) have riled the hemp and CBD sectors, with opinions divided on what the rule would mean if enacted in its current form
Charlotte’s Web has been denied a US trademark on appeal – a ruling that has serious implications for any company in the CBD sector selling food, drink or dietary supplement products in the US
Canopy, the Canadian cannabinoid company, has continued to commit heavily to BioSteel, a sports nutrition company in which Canopy now owns the majority share.
Canadian cannabinoid firm Canopy Growth has signed a multi-year deal with NFL quarterback Patrick Mahomes as part of its advance into the sports nutrition market
The opinion (which is not yet set by the EC but appears to be the way the organisation is thinking) is based on a literal reading of the 1961 UN Narcotics Convention.
Clinical research guidance from the US Food and Drug Administration (FDA) should provide further impetus for cannabis research, which is certain to have an impact on the CBD market
Authorities have been very tight lipped about the details of the proposed regulations and little is known beyond the title of the document.
Current indications are that the EC is leaning heavily towards the idea that CBD does indeed count as a narcotic under the 1961 Un Convention.
Current indications are that the EC is leaning heavily towards the idea that CBD does indeed count as a narcotic under the 1961 Un Convention.
Although opponents of the ban had their positive result overthrown by the Seventh Circuit Court of Appeals, the decision is not as bad as a headline might suggest.
The Seventh Circuit Court of Appeals has dealt a blow to challengers of Indiana’s smokable hemp ban, ruling that the lower court went too far in restricting the enforcement of Indiana’s ban
Hemp companies, politicians and legal experts have welcomed guidance from US monetary regulators that should drive up the number of financial institutions servicing the sector
Colorado has joined the list of US states selling hemp-derived CBD products through cannabis dispensaries
A new line of sparkling CBD drinks is to be launched in the Colorado market in what may be an indication of how high-profile companies approach the CBD market during its continued period of uncertainty
The company behind the world’s first injectable CBD product has issued a voluntary recall, while the US FDA continues to send warning letters over unsubstantiated health claims
With the federal legalisation of hemp in the US , states were left to enact their own legislation to adapt. CBD-Intel provides an overview of US law on smokable hemp, along with analysis of each state’s rules
The US Drug Enforcement Administration (DEA) has removed Epidiolex, the only CBD drug so far approved by the US Food and Drug Administration (FDA), from its list of controlled substances
The Food and Drug Administration (FDA) has released an update on CBD enforcement to members of Congress
The US Department of Agriculture (USDA) is to temporarily delay enforcement of two controversial provisions in its interim hemp production rule after receiving a large quantity of critical feedback
Leading members of the US Congress are again pushing for the legalisation of dietary supplements containing hemp-derived CBD, currently banned by the Food and Drug Administration (FDA)
This report identifies and answers some of the most important questions surrounding the legality and regulation of CBD and food in the US
Jurisdiction confusion and regulatory uncertainty make it a stressful business moving CBD and hemp products across the US border
Federal banking regulators have issued guidance clarifying the legal status of banks doing business with hemp firms, permitting it as long as they follow and comply with the relevant requirements of the Bank Secrecy Act
Expect to see more CBD-related lawsuits from individual US consumers over the next year – and increased litigation could help to speed up regulatory clarification
The US Department of Agriculture hemp rules have been published, developing the 2018 federal Farm Bill in time to offer guidance to farmers for the 2020 hemp growing season. This report provides in-depth information
Cannabis-based vaping products won’t be legally available in Canada’s second-largest province “for the time being” after the Quebec government-owned cannabis monopoly decided to keep them off the shelves
A “minibus spending package” in the US Senate will provide hemp stakeholders with protection as well as funding for further work by federal institutions in the sector
The US Department of Agriculture (USDA) has announced that it is preparing to release the interim final rules governing a national hemp product program
Despite various bodies making steps towards legalisation, the existing legal environment for CBD across the US remains a patchwork of contradictory policies
CBD and hemp regulation across the US remains mixed; this report takes the three main provisions of the 2018 US Farm Bill, and analyses each state’s implementation
US Senate majority leader Mitch McConnell is to attach funding to the agricultural appropriations bill to speed the FDA’s preliminary steps towards rulemaking for CBD products
Rising demand for hemp products could soon make it an important cash crop for America but both industry and regulators must change to meet evolving demands and challenges
While the US FDA looks at paths for providing CBD research and routes to market, Congress may have a further opportunity to encourage legal developments in that direction
Attention in Washington is increasingly focused on CBD, with the US Congress striving to address regulation and the FDA promising policy action soon
Banking associations from all across the US have written to the Senate to advocate for a hearing on cannabis banking reform
The US Department of Veterans Affairs has opposed three CBD-related bills in Congress, leading some to wonder if the agency is looking to punish veterans who admit using medical cannabis
US attorney general William Barr has said the current patchwork regulatory situation for CBD in the country is “intolerable” and given qualified support to an act which would allow states to decide their own policies
Several US states and territories are reporting changes to hemp policies following the passing of the 2018 US Farm Bill. One surprisingly positive example is Pennsylvania, which is backing growth
Pro-cannabis measures are expected to receive at least 18 more votes of support in the new US Congress, according to exclusive research by CBD-Intel, with more than 60 new Representatives supporting legalisation
The US Congress has approved a compromise version of the 2018 Farm Bill which will remove industrial hemp from the federal narcotics Schedule 1 list, potentially giving a green light to development of the CBD industry
Language in the Senate version of the 2018 US Farm Bill could lead to sweeping changes in the CBD sector – and significant bipartisan support appears to exist to pass it after the November mid-term elections
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.
Free sample available
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
